Clinical trialNCT03906071CompletedPhase 3Interventional

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

SponsorMirati Therapeutics Inc.Enrollment577Metastatic Non-Squamous Non-Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bristol-Myers Squibb
Bristol-Myers Squibb
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

261 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Local Institution - 005-201
Brasschaat, Belgium
Local Institution - 005-200
Charleroi, Belgium
Local Institution - 005-206
Edegem, Belgium
Local Institution - 005-202
Ghent, Belgium
Local Institution - 005-207
Ghent, Belgium
Local Institution - 005-205
Roeselare, Belgium
Local Institution - 005-204
Ronse, Belgium
Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne
Yvoir, Belgium

Canada

Local Institution - 005-259
Calgary, Alberta, Canada
Local Institution - 005-250
Moncton, New Brunswick, Canada
Saint John Regional Hospital
Saint John, New Brunswick, Canada
Local Institution - 005-252
Hamilton, Ontario, Canada
Local Institution - 005-251
Toronto, Ontario, Canada
Local Institution - 005-257
Windsor, Ontario, Canada
Local Institution - 005-255
Montreal, Quebec, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Local Institution - 005-258
Québec, Canada

France

Local Institution - 005-307
Brest, France
Local Institution - 005-310
Bron, France
Local Institution - 005-311
Créteil, France
Local Institution - 005-303
Dijon, France
Local Institution - 005-309
Le Mans, France
Local Institution - 005-308
Limoges, France
Local Institution - 005-317
Lyon, France
Local Institution - 005-301
Marseille, France
Local Institution - 005-312
Marseille, France
Local Institution - 005-313
Montpellier, France
Local Institution - 005-306
Mulhouse, France
Local Institution - 005-302
Paris, France
Local Institution - 005-314
Rouen, France
Local Institution - 005-316
Saint-Herblain, France
Local Institution - 005-305
Strasbourg, France
Local Institution - 005-304
Villejuif, France

Germany

Local Institution - 005-400
Bad Berka, Germany
Local Institution - 005-418
Berlin, Germany
Local Institution - 005-401
Bonn, Germany
Local Institution - 005-412
Cologne, Germany
Local Institution - 005-419
Essen, Germany
Local Institution - 005-406
Esslingen am Neckar, Germany
Local Institution - 005-403
Gauting, Germany

221 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jul 2019
Primary completion: 20 Mar 2023
Completion: 30 Sept 2025
Last update posted: 21 Oct 2025
Registered enrollment: 577
Registry id: NCT03906071

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.